Werewolf Therapeutics, Inc. Stock Price, News & Analysis

Werewolf Therapeutics (Nasdaq: HOWL) announced the publication of preclinical data for mWTX-330, an Interleukin-12 INDUKINE molecule, in Cancer Immunology Research. This study demonstrates that mWTX-330 effectively stimulates an anti-tumor immune response by selectively delivering IL-12 to the tumor microenvironment while minimizing systemic toxicity. Key findings include robust immune activation in multiple tumor models and improved T-cell activity without signs of exhaustion. The company is preparing for a Phase 1 clinical trial for WTX-330 in patients with advanced solid tumors or lymphoma resistant to checkpoint inhibitors. The trial aims to evaluate safety and efficacy, marking a significant step in Werewolf's mission to enhance cancer treatments through targeted immune activation.

Werewolf Therapeutics (Nasdaq: HOWL) announced significant advancements in its clinical trials and financial position. The company is preparing to release initial clinical data for its IL-2 INDUKINE WTX-124 monotherapy in Q4 2023, while the first patient has been dosed in the IL-12 INDUKINE WTX-330 trial. Furthermore, it nominated WTX-712 for preclinical development. The financial update shows a cash position of $129.3 million, with guidance extended to cover operations through Q4 2024. Collaboration revenue rose to $7.3 million in Q4 2022, a notable increase from 2021, amidst rising expenses primarily related to R&D.

Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the publication of abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. Key presentations include:

• Abstract 1829: Generation of IL-21 INDUKINE™ molecules for cancer treatment on April 17, 9:00 a.m. - 12:30 p.m.
• Abstract CT133: Phase 1/1b study of WTX-124, April 17, 1:30 p.m. - 5:00 p.m.
• Abstract CT254: First-in-human study of WTX-330 on April 18, 1:30 p.m. - 5:00 p.m.

Werewolf is focused on conditionally activated therapeutics to enhance the immune response against cancer.

Werewolf Therapeutics, a biopharmaceutical company focused on cancer treatment, announced its upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled from April 14-19 in Orlando, Florida. The abstract, numbered 1829, details the generation of IL-21 INDUKINE™ molecules aimed at activating the immune system while minimizing side effects. The presentation will occur on April 17 from 9:00 a.m. to 12:30 p.m. at Poster Section 24, Board Number 1. The company utilizes its proprietary PREDATOR™ platform to develop conditionally activated therapeutics targeting solid tumors, including its lead candidates, WTX-124 and WTX-330.